{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:24:23Z","timestamp":1791228263817,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005440","name":"Center for Scientific Review","doi-asserted-by":"publisher","award":["R01AG054473"],"award-info":[{"award-number":["R01AG054473"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005440","name":"Center for Scientific Review","doi-asserted-by":"publisher","award":["R01AG052414"],"award-info":[{"award-number":["R01AG052414"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005155","name":"Azrieli Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012171","name":"Ontario Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CGS-D"],"award-info":[{"award-number":["CGS-D"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014405","name":"Centre for Addiction and Mental Health Foundation","doi-asserted-by":"publisher","award":["Discovery Fund"],"award-info":[{"award-number":["Discovery Fund"]}],"id":[{"id":"10.13039\/100014405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11307-022-01779-1","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T16:04:36Z","timestamp":1666109076000},"page":"513-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Head-to-Head Comparison of Tau-PET Radioligands for Imaging TDP-43 in Post-Mortem ALS Brain"],"prefix":"10.1007","volume":"25","author":[{"given":"Ashley C.","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassis","family":"Varlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Haung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-5125","authenticated-orcid":false,"given":"Neil","family":"Vasdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"1779_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000351153","volume":"41","author":"A Chi\u00f2","year":"2013","unstructured":"Chi\u00f2 A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118\u2013130. https:\/\/doi.org\/10.1159\/000351153","journal-title":"Neuroepidemiology"},{"key":"1779_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/archneurol.2008.558","volume":"66","author":"F Geser","year":"2009","unstructured":"Geser F, Martinez-Lage M, Robinson J et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66:180\u2013189. https:\/\/doi.org\/10.1001\/archneurol.2008.558","journal-title":"Arch Neurol"},{"key":"1779_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nn.3584","volume":"17","author":"AE Renton","year":"2014","unstructured":"Renton AE, Chi\u00f2 A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17:17\u201323. https:\/\/doi.org\/10.1038\/nn.3584","journal-title":"Nat Neurosci"},{"key":"1779_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12883-018-1091-7","volume":"18","author":"V Majumder","year":"2018","unstructured":"Majumder V, Gregory JM, Barria MA et al (2018) TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol 18:90. https:\/\/doi.org\/10.1186\/s12883-018-1091-7","journal-title":"BMC Neurol"},{"key":"1779_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130\u2013133. https:\/\/doi.org\/10.1126\/science.1134108","journal-title":"Science"},{"key":"1779_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602\u2013611. https:\/\/doi.org\/10.1016\/j.bbrc.2006.10.093","journal-title":"Biochem Biophys Res Commun"},{"key":"1779_CR7","doi-asserted-by":"publisher","first-page":"7789","DOI":"10.1007\/s12035-018-0947-6","volume":"55","author":"E Feneberg","year":"2018","unstructured":"Feneberg E, Gray E, Ansorge O et al (2018) Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol 55:7789\u20137801. https:\/\/doi.org\/10.1007\/s12035-018-0947-6","journal-title":"Mol Neurobiol"},{"key":"1779_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-010-0658-1","volume":"119","author":"GG Kovacs","year":"2010","unstructured":"Kovacs GG, Botond G, Budka H (2010) Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol 119:389\u2013408. https:\/\/doi.org\/10.1007\/s00401-010-0658-1","journal-title":"Acta Neuropathol"},{"key":"1779_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/ana.23937","volume":"74","author":"J Brettschneider","year":"2013","unstructured":"Brettschneider J, Del Tredici K, Toledo JB et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20\u201338. https:\/\/doi.org\/10.1002\/ana.23937","journal-title":"Ann Neurol"},{"key":"1779_CR10","unstructured":"Tamara Seredenina P (2019) Discovery and development of diagnostics and therapeutics for TDP-43 proteinopathies. Lisbon, Portugal"},{"key":"1779_CR11","first-page":"613","volume":"59","author":"A Brooks","year":"2018","unstructured":"Brooks A, Tanzey S, Shao X, Scott P (2018) Binding potential of radioligand [18F]FL2-b by autoradiography in amyotrophic lateral sclerosis and lewy body dementia. J Nucl Med 59:613","journal-title":"J Nucl Med"},{"key":"1779_CR12","first-page":"1038","volume":"61","author":"S Tanzey","year":"2020","unstructured":"Tanzey S, Brooks A, Shao X, Scott P (2020) Extraction of enriched phosphorylated TDP43 from ALS tissue for evaluation of new TDP-43 radiotracers. J Nucl Med 61:1038\u20131038","journal-title":"J Nucl Med"},{"key":"1779_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/wco.0000000000000728","volume":"32","author":"J Kassubek","year":"2019","unstructured":"Kassubek J, Pagani M (2019) Imaging in amyotrophic lateral sclerosis: MRI and PET. Curr Opin Neurol 32:740\u2013746. https:\/\/doi.org\/10.1097\/wco.0000000000000728","journal-title":"Curr Opin Neurol"},{"key":"1779_CR14","doi-asserted-by":"publisher","unstructured":"Harada R, Okamura N, Furumoto S, Yanai K (2018) Imaging protein misfolding in the brain using \u03b2-sheet ligands. Front Neurosci 12. https:\/\/doi.org\/10.3389\/fnins.2018.00585","DOI":"10.3389\/fnins.2018.00585"},{"key":"1779_CR15","doi-asserted-by":"crossref","unstructured":"Klunk WE, Wang Y, Huang GF, et al (2001) Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. In: Life Sci. Netherlands, pp 1471\u201384","DOI":"10.1016\/S0024-3205(01)01232-2"},{"key":"1779_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","volume":"42","author":"CA Mathis","year":"2012","unstructured":"Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography \u03b2-amyloid plaque imaging agents. Semin Nucl Med 42:423\u2013432","journal-title":"Semin Nucl Med"},{"key":"1779_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L et al (2019) Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry 24:1112\u20131134. https:\/\/doi.org\/10.1038\/s41380-018-0342-8","journal-title":"Mol Psychiatry"},{"key":"1779_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nature12481","volume":"501","author":"M Jucker","year":"2013","unstructured":"Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45\u201351. https:\/\/doi.org\/10.1038\/nature12481","journal-title":"Nature"},{"key":"1779_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-013-1089-6","volume":"125","author":"EH Bigio","year":"2013","unstructured":"Bigio EH, Wu JY, Deng HX et al (2013) Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol 125:463\u2013465","journal-title":"Acta Neuropathol"},{"key":"1779_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000109758","volume":"16","author":"LK Kwong","year":"2008","unstructured":"Kwong LK, Uryu K, Trojanowski JQ, Lee VM-Y (2008) TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16:41\u201351. https:\/\/doi.org\/10.1159\/000109758","journal-title":"Neurosignals"},{"key":"1779_CR21","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1021\/acs.jpclett.5b00918","volume":"6","author":"M Mompe\u00e1n","year":"2015","unstructured":"Mompe\u00e1n M, Herv\u00e1s R, Xu Y et al (2015) Structural evidence of amyloid fibril formation in the putative aggregation domain of TDP-43. J Phys Chem Lett 6:2608\u20132615. https:\/\/doi.org\/10.1021\/acs.jpclett.5b00918","journal-title":"J Phys Chem Lett"},{"key":"1779_CR22","doi-asserted-by":"publisher","unstructured":"Robinson JL, Geser F, Stieber A, et al (2013) TDP-43 skeins show properties of amyloid in a subset of ALS cases. ActaNeuropathol 121\u2013131. https:\/\/doi.org\/10.1007\/s00401-012-1055-8","DOI":"10.1007\/s00401-012-1055-8"},{"key":"1779_CR23","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-021-21912-y","volume":"12","author":"Q Li","year":"2021","unstructured":"Li Q, Babinchak WM, Surewicz WK (2021) Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nat Commun 12:1620. https:\/\/doi.org\/10.1038\/s41467-021-21912-y","journal-title":"Nat Commun"},{"key":"1779_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41594-019-0248-4","volume":"26","author":"Q Cao","year":"2019","unstructured":"Cao Q, Boyer DR, Sawaya MR et al (2019) Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat Struct Mol Biol 26:619\u2013627. https:\/\/doi.org\/10.1038\/s41594-019-0248-4","journal-title":"Nat Struct Mol Biol"},{"key":"1779_CR25","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/jnnp-2017-316402","volume":"89","author":"WR Bevan-Jones","year":"2018","unstructured":"Bevan-Jones WR, Cope TE, Jones PS et al (2018) [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry 89:1032\u20131037. https:\/\/doi.org\/10.1136\/jnnp-2017-316402","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1779_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"C-F Xia","year":"2013","unstructured":"Xia C-F, Arteaga J, Chen G et al (2013) [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 9:666\u2013676. https:\/\/doi.org\/10.1016\/j.jalz.2012.11.008","journal-title":"Alzheimer\u2019s Dement"},{"key":"1779_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z et al (2016) Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med 57:1599\u20131606. https:\/\/doi.org\/10.2967\/jnumed.115.171678","journal-title":"J Nucl Med"},{"key":"1779_CR28","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1007\/s00259-020-04880-1","volume":"47","author":"ME Schmidt","year":"2020","unstructured":"Schmidt ME, Janssens L, Moechars D et al (2020) Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 47:3176\u20133185. https:\/\/doi.org\/10.1007\/s00259-020-04880-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1779_CR29","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","volume":"46","author":"S Sanabria Bohorquez","year":"2019","unstructured":"Sanabria Bohorquez S, Marik J, Ogasawara A et al (2019) [18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 46:2077\u20132089. https:\/\/doi.org\/10.1007\/s00259-019-04399-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1779_CR30","doi-asserted-by":"publisher","first-page":"P146","DOI":"10.1016\/j.jalz.2017.06.2573","volume":"13","author":"H Shimada","year":"2017","unstructured":"Shimada H, Kitamura S, Ono M et al (2017) [IC-P-198]: First-in-human PET study with 18F-AM-PBB3 and 18F-PM-PBB3. Alzheimer\u2019s Dement 13:P146\u2013P146. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2573","journal-title":"Alzheimer\u2019s Dement"},{"key":"1779_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1021\/acschemneuro.0c00801","volume":"12","author":"A Lindberg","year":"2021","unstructured":"Lindberg A, Knight AC, Sohn D et al (2021) Radiosynthesis, in vitro and in vivo evaluation of [18F]CBD-2115 as a first-in-class radiotracer for imaging 4R-tauopathies. ACS Chem Neurosci 12:596\u2013602. https:\/\/doi.org\/10.1021\/acschemneuro.0c00801","journal-title":"ACS Chem Neurosci"},{"key":"1779_CR32","unstructured":"Sohn D (2019) Selective ligands for tau aggregates. WIPOI Bureau, Karen and Sten Mortstedt CBD Solutions AB."},{"key":"1779_CR33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/brain\/aww339","volume":"140","author":"M Ono","year":"2017","unstructured":"Ono M, Sahara N, Kumata K et al (2017) Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140:764\u2013780. https:\/\/doi.org\/10.1093\/brain\/aww339","journal-title":"Brain"},{"key":"1779_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai K, Ono M, Kubota M et al (2021) High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies. Neuron 109:42-58.e8. https:\/\/doi.org\/10.1016\/j.neuron.2020.09.042","journal-title":"Neuron"},{"key":"1779_CR35","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/acschemneuro.8b00093","volume":"9","author":"NA Murugan","year":"2018","unstructured":"Murugan NA, Nordberg A, \u00c5gren H (2018) Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: insight from computational modeling. ACS Chem Neurosci 9:1757\u20131767. https:\/\/doi.org\/10.1021\/acschemneuro.8b00093","journal-title":"ACS Chem Neurosci"},{"key":"1779_CR36","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.112.114785","volume":"54","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Pejoska S, Mulligan RS et al (2013) Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia. J Nucl Med 54:880\u2013886. https:\/\/doi.org\/10.2967\/jnumed.112.114785","journal-title":"J Nucl Med"},{"key":"1779_CR37","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1038\/s41598-019-42625-9","volume":"9","author":"R Smith","year":"2019","unstructured":"Smith R, Santillo AF, Wald\u00f6 ML et al (2019) 18F-Flortaucipir in TDP-43 associated frontotemporal dementia. Sci Rep 9:6082. https:\/\/doi.org\/10.1038\/s41598-019-42625-9","journal-title":"Sci Rep"},{"key":"1779_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","volume":"11","author":"RM Tsai","year":"2019","unstructured":"Tsai RM, Bejanin A, Lesman-Segev O et al (2019) 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer\u2019s Res Ther 11:13. https:\/\/doi.org\/10.1186\/s13195-019-0470-7","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1779_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marqui\u00e9","year":"2015","unstructured":"Marqui\u00e9 M, Normandin MD, Vanderburg CR et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787\u2013800. https:\/\/doi.org\/10.1002\/ana.24517","journal-title":"Ann Neurol"},{"key":"1779_CR40","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","volume":"12","author":"K Sander","year":"2016","unstructured":"Sander K, Lashley T, Gami P et al (2016) Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias. Alzheimer\u2019s Dement 12:1116\u20131124. https:\/\/doi.org\/10.1016\/j.jalz.2016.01.003","journal-title":"Alzheimer\u2019s Dement"},{"key":"1779_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P et al (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58. https:\/\/doi.org\/10.1186\/s40478-016-0315-6","journal-title":"Acta Neuropathol Commun"},{"key":"1779_CR42","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1021\/acschemneuro.1c00536","volume":"12","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Li J, Nordberg A, \u00c5gren H (2021) Dissecting the binding profile of PET tracers to corticobasal degeneration tau fibrils. ACS Chem Neurosci 12:3487\u20133496. https:\/\/doi.org\/10.1021\/acschemneuro.1c00536","journal-title":"ACS Chem Neurosci"},{"key":"1779_CR43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.dadm.2018.01.007","volume":"10","author":"L Lemoine","year":"2018","unstructured":"Lemoine L, Leuzy A, Chiotis K et al (2018) Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimer\u2019s Dement 10:232\u2013236. https:\/\/doi.org\/10.1016\/j.dadm.2018.01.007","journal-title":"Alzheimer\u2019s Dement"},{"key":"1779_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mds.27271","volume":"33","author":"C Vermeiren","year":"2018","unstructured":"Vermeiren C, Motte P, Viot D et al (2018) The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord 33:273\u2013281. https:\/\/doi.org\/10.1002\/mds.27271","journal-title":"Mov Disord"},{"key":"1779_CR45","doi-asserted-by":"publisher","unstructured":"Jie CVML, Treyer V, Schibli R, Mu L (2021) TauvidTM: The first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals 14. https:\/\/doi.org\/10.3390\/ph14020110","DOI":"10.3390\/ph14020110"},{"key":"1779_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-3-7091-9324-2_31","volume":"41","author":"SS Jossan","year":"1994","unstructured":"Jossan SS, Ekblom J, Aquilonius SM, Oreland L (1994) Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography. J Neural Transm Suppl 41:243\u2013248. https:\/\/doi.org\/10.1007\/978-3-7091-9324-2_31","journal-title":"J Neural Transm Suppl"},{"key":"1779_CR47","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1152\/physrev.00049.2010","volume":"92","author":"ML James","year":"2012","unstructured":"James ML, Gambhir SS (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92:897\u2013965. https:\/\/doi.org\/10.1152\/physrev.00049.2010","journal-title":"Physiol Rev"},{"key":"1779_CR48","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1007\/s00259-022-05822-9","volume":"49","author":"JP Wright","year":"2022","unstructured":"Wright JP, Goodman JR, Lin Y-G et al (2022) Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation. Eur J Nucl Med Mol Imaging 49:3797\u20133808. https:\/\/doi.org\/10.1007\/s00259-022-05822-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1779_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/jad-200287","volume":"76","author":"Y Su","year":"2020","unstructured":"Su Y, Fu J, Yu J et al (2020) Tau PET imaging with [18F]PM-PBB3 in frontotemporal dementia with MAPT mutation. J Alzheimers Dis 76:149\u2013157. https:\/\/doi.org\/10.3233\/jad-200287","journal-title":"J Alzheimers Dis"},{"key":"1779_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/ncn3.12463","volume":"9","author":"Y Ohta","year":"2021","unstructured":"Ohta Y, Shimada H, Ikegami K et al (2021) A case of Kii amyotrophic lateral sclerosis\/parkinsonism dementia complex presenting as progressive parkinsonism with corresponding tau imaging. Neurol Clin Neurosci 9:124\u2013126. https:\/\/doi.org\/10.1111\/ncn3.12463","journal-title":"Neurol Clin Neurosci"},{"key":"1779_CR51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00401-021-02294-3","volume":"141","author":"Y Shi","year":"2021","unstructured":"Shi Y, Murzin AG, Falcon B et al (2021) Cryo-EM structures of tau filaments from Alzheimer\u2019s disease with PET ligand APN-1607. Acta Neuropathol 141:697\u2013708. https:\/\/doi.org\/10.1007\/s00401-021-02294-3","journal-title":"Acta Neuropathol"},{"key":"1779_CR52","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/mds.27029","volume":"32","author":"A Perez-Soriano","year":"2017","unstructured":"Perez-Soriano A, Arena JE, Dinelle K et al (2017) PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord 32:1016\u20131024. https:\/\/doi.org\/10.1002\/mds.27029","journal-title":"Mov Disord"},{"key":"1779_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147131","volume":"1749","author":"P Miranda-Azpiazu","year":"2020","unstructured":"Miranda-Azpiazu P, Svedberg M, Higuchi M et al (2020) Identification and in vitro characterization of C05\u201301, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res 1749:147131. https:\/\/doi.org\/10.1016\/j.brainres.2020.147131","journal-title":"Brain Res"},{"key":"1779_CR54","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mds.27013","volume":"32","author":"S Koga","year":"2017","unstructured":"Koga S, Ono M, Sahara N et al (2017) Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to \u03b1-synuclein pathology. Mov Disord 32:884\u2013892. https:\/\/doi.org\/10.1002\/mds.27013","journal-title":"Mov Disord"},{"key":"1779_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jocn.2020.04.088","volume":"78","author":"S Das","year":"2020","unstructured":"Das S, Zhang Z, Ang LC (2020) Clinicopathological overlap of neurodegenerative diseases: a comprehensive review. J Clin Neurosci 78:30\u201333. https:\/\/doi.org\/10.1016\/j.jocn.2020.04.088","journal-title":"J Clin Neurosci"},{"key":"1779_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/neup.12428","volume":"38","author":"T Takeda","year":"2018","unstructured":"Takeda T (2018) Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis\/frontotemporal lobar degeneration. Neuropathology 38:72\u201381. https:\/\/doi.org\/10.1111\/neup.12428","journal-title":"Neuropathology"},{"key":"1779_CR57","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00401-004-0843-1","volume":"107","author":"RL Hamilton","year":"2004","unstructured":"Hamilton RL, Bowser R (2004) Alzheimer disease pathology in amyotrophic lateral sclerosis. Acta Neuropathol 107:515\u2013522. https:\/\/doi.org\/10.1007\/s00401-004-0843-1","journal-title":"Acta Neuropathol"},{"key":"1779_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40478-016-0301-z","volume":"4","author":"R Behrouzi","year":"2016","unstructured":"Behrouzi R, Liu X, Wu D et al (2016) Pathological tau deposition in motor neurone disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathol Commun 4:33. https:\/\/doi.org\/10.1186\/s40478-016-0301-z","journal-title":"Acta Neuropathol Commun"},{"key":"1779_CR59","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3233\/JAD-151052","volume":"51","author":"CH Lyoo","year":"2016","unstructured":"Lyoo CH, Cho H, Choi JY et al (2016) (2016) Tau accumulation in primary motor cortex of variant Alzheimer\u2019s disease with spastic paraparesis. J Alzheimers Dis 51:671\u2013675. https:\/\/doi.org\/10.3233\/JAD-151052","journal-title":"J Alzheimers Dis"},{"key":"1779_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-021-04199-3","volume":"601","author":"D Arseni","year":"2022","unstructured":"Arseni D, Hasegawa M, Murzin AG et al (2022) Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601:139\u2013143. https:\/\/doi.org\/10.1038\/s41586-021-04199-3","journal-title":"Nature"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01779-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:54:35Z","timestamp":1683791675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01779-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01779-1","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All tissues were obtained in accordance with the guidelines put forth by the Centre for Addiction and Mental Health Research Ethics Board (protocol no. 036\u20132019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"A.C.K. and P.M. are employed by Takeda Pharmaceutical Company. N.V. is a co-founder of MedChem Imaging, Inc. All authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}